Combination Chemotherapy for Relapsed/Refractory Blood Cancers
Phase 2
42
about 10 years
15+
1 site in TX
About this study
This trial is testing a combination of chemotherapy drugs to see if it works in people with certain types of blood cancers that have returned or not responded to previous treatment. The treatment includes medications like clofarabine, etoposide, and bortezomib, which work by killing cancer cells or stopping them from growing.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Ofatumumab
- 2.Receive Pegfilgrastim
- 3.Receive Rituximab
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bortezomib, clofarabine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), dexamethasone, etoposide, ofatumumab, pegfilgrastim, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
injection (Injection), injection, intravenous, infusion, ocular
Primary: Incidence of adverse events, Overall response rate (ORR) (Phase II)
Secondary: Event free survival, Overall survival
Oncology